Ito Yasuhiro, Miyauchi Akira, Nakamura Yasushi, Miya Akihiro, Kobayashi Kaoru, Kakudo Kennichi
Department of Surgery, Kuma Hospital, Kobe, Japan.
Am J Clin Pathol. 2007 Feb;127(2):230-6. doi: 10.1309/VM7E52B6U9Q729DQ.
Intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) is a rare malignant tumor having histopathologic features similar to those of squamous cell carcinoma of the thyroid and other organs and a more favorable prognosis. It is thought to originate from ectopic thymic tissue or embryonic thymic rest in or adjacent to the thyroid. We investigated clinicopathologic features of 25 cases of ITET/CASTLE. The sensitivity and specificity of the pathologic diagnosis of ITET/CASTLE by immunohistochemical staining with CD5, a marker of carcinoma of thymic origin, were 82% and 100%, respectively. The 5- and 10-year cause-specific survival rates were 90% and 82%, respectively. Nodal metastasis and tumor extension predict a worse prognosis. Of 22 patients who had curative surgery, 10 (45%) underwent adjuvant radiation therapy, and no locoregional recurrence was seen in any of them. This is the first study demonstrating the survival curve for patients with ITET/CASTLE. Our findings suggest that curative resection followed by radiation therapy may effectively prevent locoregional recurrence and CD5 immunostaining is useful for diagnosing ITET/CASTLE.
甲状腺内上皮性胸腺瘤(ITET)/具有胸腺样分化的癌(CASTLE)是一种罕见的恶性肿瘤,其组织病理学特征与甲状腺及其他器官的鳞状细胞癌相似,预后相对较好。它被认为起源于甲状腺内或其附近的异位胸腺组织或胚胎胸腺残体。我们对25例ITET/CASTLE的临床病理特征进行了研究。采用胸腺源性癌标志物CD5进行免疫组化染色对ITET/CASTLE进行病理诊断的敏感性和特异性分别为82%和100%。5年和10年病因特异性生存率分别为90%和82%。淋巴结转移和肿瘤侵犯提示预后较差。在22例接受根治性手术的患者中,10例(45%)接受了辅助放疗,且均未出现局部区域复发。这是第一项展示ITET/CASTLE患者生存曲线的研究。我们的研究结果表明,根治性切除后行放疗可有效预防局部区域复发,且CD5免疫染色有助于ITET/CASTLE的诊断。